Ginkgo Bioworks 

$6.2
540
+$0.07+1.14% Today

Statistics

Day High
6.24
Day Low
5.65
52W High
16.14
52W Low
5.48
Volume
1,231,660
Avg. Volume
1,147,500
Mkt Cap
309.64M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-2.73
-2.18
-1.63
-1.08
Expected EPS
-1.21115
Actual EPS
N/A

Financials

-183.81%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
340.31MRevenue
-625.53MNet Income

Analyst Ratings

$8.50Average Price Target
The highest estimate is 12.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
0%
Sell
50%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DNA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Twist Bioscience
TWST
Mkt Cap1.99B
Twist Bioscience Corporation operates in the synthetic biology field, offering DNA synthesis products that compete with Ginkgo Bioworks' platform for programming cells.
Synlogic
SYBX
Mkt Cap19.77M
Synlogic, Inc. is engaged in the development of therapeutics that leverage synthetic biology, competing in the biotech space where Ginkgo Bioworks also operates.
Codexis
CDXS
Mkt Cap213.93M
Codexis, Inc. specializes in protein engineering and enzyme optimization, competing with Ginkgo Bioworks in the field of bio-catalysis and bio-manufacturing.
Evogene
EVGN
Mkt Cap11.24M
Evogene Ltd. applies computational biology and synthetic biology to develop products in agriculture, competing with Ginkgo Bioworks in the agri-biotech sector.
Pacific Biosciences of California
PACB
Mkt Cap702.87M
Pacific Biosciences of California, Inc. provides sequencing systems that compete with Ginkgo Bioworks' offerings in the genomics and genetic engineering space.
Illumina
ILMN
Mkt Cap18.99B
Illumina, Inc. is a leader in genomics and DNA sequencing technologies, indirectly competing with Ginkgo Bioworks by enabling synthetic biology research and applications.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics AG focuses on gene editing technologies, competing in the broader biotech space for genetic engineering applications, overlapping with Ginkgo's market.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine, Inc. is involved in gene editing, competing in the genetic modification space, which is relevant to Ginkgo Bioworks' synthetic biology applications.

About

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Show more...
CEO
Dr. Jason Kelly Ph.D.
Employees
834
Country
US
ISIN
US37611X2099

Listings

0 Comments

Share your thoughts

FAQ

What is Ginkgo Bioworks stock price today?
The current price of DNA is $6.2 USD — it has increased by +1.14% in the past 24 hours. Watch Ginkgo Bioworks stock price performance more closely on the chart.
What is Ginkgo Bioworks stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Ginkgo Bioworks stocks are traded under the ticker DNA.
Is Ginkgo Bioworks stock price growing?
DNA stock has fallen by -14.93% compared to the previous week, the month change is a -7.24% fall, over the last year Ginkgo Bioworks has showed a +10.63% increase.
What is Ginkgo Bioworks market cap?
Today Ginkgo Bioworks has the market capitalization of 309.64M
When is the next Ginkgo Bioworks earnings date?
Ginkgo Bioworks is going to release the next earnings report on May 13, 2026.
What were Ginkgo Bioworks earnings last quarter?
DNA earnings for the last quarter are -1.41 USD per share, whereas the estimation was -1.46 USD resulting in a +3.09% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ginkgo Bioworks revenue for the last year?
Ginkgo Bioworks revenue for the last year amounts to 340.31M USD.
What is Ginkgo Bioworks net income for the last year?
DNA net income for the last year is -625.53M USD.
How many employees does Ginkgo Bioworks have?
As of April 01, 2026, the company has 834 employees.
In which sector is Ginkgo Bioworks located?
Ginkgo Bioworks operates in the Health Care sector.
When did Ginkgo Bioworks complete a stock split?
The last stock split for Ginkgo Bioworks was on August 20, 2024 with a ratio of 1:40.
Where is Ginkgo Bioworks headquartered?
Ginkgo Bioworks is headquartered in Boston, US.